Medulloblastomas in adults: Prognostic factors and lessons from paediatrics

Current Opinion in Neurology

Volumn 24, Issue 6, 2011, Pages 626-632

  Fellay, Cristina Nay ^a,b   Frappaz, Didier ^c   Sunyach, Marie P ^c   Franceschi, Enrico ^d   Brandes, Alba A ^d   Stupp, Roger ^b,e  

^a UNIVERSITY OF BERN   (Switzerland)

^b Department of Oncology and Haematology   (Switzerland)

^c CENTRE LÉON BÉRARD   (France)

^d Azienda USL di Bologna   (Italy)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

adult medulloblastomas; molecular factors; prognostic factors; treatment

Indexed keywords

BETA CATENIN; CISPLATIN; CYCLIN DEPENDENT KINASE 6; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; NEUROTROPHIN 3 RECEPTOR; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

AGE; CANCER SURGERY; CANCER SURVIVAL; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME LOSS; CONTROLLED CLINICAL TRIAL (TOPIC); COPY NUMBER VARIATION; FOLLOW UP; GENE ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HIGH RISK PATIENT; HISTOLOGY; HUMAN; MEDULLOBLASTOMA; METASTASIS; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; ONCOGENE C MYC; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TUMOR CLASSIFICATION;

ADULT; BETA CATENIN; CHILD; CHILD, PRESCHOOL; GENE EXPRESSION PROFILING; HUMANS; MEDULLOBLASTOMA; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 81855221751     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32834cd4b1     Document Type: Review

References (61)

1. CBTRUS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2011.
2. Louis D, Ohgaki H, Wiestler O, Cavenee W.WHOclassification of tumours of the central nervous system. Lyon: International Agency for Research on Cancer; 2007.
3. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114:97-109. (Pubitemid 47103521)
4. Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 1969; 93:1351-1359.
5. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999; 17:832-845. (Pubitemid 29109313)
6. Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990; 72:572-582. (Pubitemid 20113683)
7. Tait DM, Thornton-Jones H, Bloom HJ, et al. Adjuvant chemotherapy for medulloblastoma: the first multicentre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990; 26:464-469. (Pubitemid 20209976)
8. Packer RJ, Sutton LN, Goldwein JW, et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 1991; 74:433-440.
9. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): longterm results from a prospective, multicentre trial. Lancet Oncol 2006; 7:813-820. (Pubitemid 44464063)
10. Kortmann RD, Kuhl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 2000; 46:269-279. (Pubitemid 30067775)
11. Von Hoff K, Hinkes B, Gerber NU, et al. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. Eur J Cancer 2009; 45:1209-1217.
12. Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 2003; 21:1581-1591. (Pubitemid 46594113)
13. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994; 81:690-698. (Pubitemid 24328694)
14. Verlooy J, Mosseri V, Bracard S, et al. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. Eur J Cancer 2006; 42:3004-3014. (Pubitemid 44667471)
15. Packer RJ, Rood BR, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg 2003; 39:60-67. (Pubitemid 36829097)
16. Oyharcabal-Bourden V, Kalifa C, Gentet JC, et al. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. J Clin Oncol 2005; 23:4726-4734. (Pubitemid 46224076)
17. Carrie C, Grill J, Figarella-Branger D, et al. Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: long-term results of MSFOP 98. J Clin Oncol 2009; 27: 1879-1883.
18. Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 2004; 31:666-675. (Pubitemid 39389018)
19. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005; 352:978-986. (Pubitemid 40349500)
20. Lai R. Survival of patients with adult medulloblastoma: a population-based study. Cancer 2008; 112:1568-1574. (Pubitemid 351441170)
21. Herrlinger U, Steinbrecher A, Rieger J, et al. Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. J Neurol 2005; 252:291-299. (Pubitemid 40562162)
22. Riffaud L, Saikali S, Leray E, et al. Survival and prognostic factors in a series of adults with medulloblastomas. J Neurosurg 2009; 111:478-487.
23. Frost PJ, Laperriere NJ, Wong CS, et al. Medulloblastoma in adults. Int J Radiat Oncol Biol Phys 1995; 32:951-957.
24. Kunschner LJ, Kuttesch J, Hess K, Yung WK. Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998. Neuro Oncol 2001; 3:167-173. (Pubitemid 33674108)
25. Menon G, Krishnakumar K, Nair S. Adult medulloblastoma: clinical profile and treatment results of 18 patients. J Clin Neurosci 2008; 15:122-126. (Pubitemid 50012528)
26. Ang C, Hauerstock D, Guiot MC, et al. Characteristics and outcomes of medulloblastoma in adults. Pediatr Blood Cancer 2008; 51:603-607.
27. Chan AW, Tarbell NJ, Black PM, et al. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery 2000; 47:623-631; discussion 631-622.
28. Chargari C, Feuvret L, Levy A, et al. Reappraisal of clinical outcome in adult medulloblastomas with emphasis on patterns of relapse. Br J Neurosurg 2010; 24:460-467.
29. Brandes AA, Ermani M, Amista P, et al. The treatment of adults with medulloblastoma: a prospective study. Int J Radiat Oncol Biol Phys 2003; 57:755-761. (Pubitemid 37194302)
30. Padovani L, Sunyach MP, Perol D, et al. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys 2007; 68:433-440. (Pubitemid 46694158)
31. Prados MD, Warnick RE, Wara WM, et al. Medulloblastoma in adults. Int J Radiat Oncol Biol Phys 1995; 32:1145-1152.
32. Carrie C, Lasset C, Alapetite C, et al. Multivariate analysis of prognostic factors in adult patients with medulloblastoma. Retrospective study of 156 patients. Cancer 1994; 74:2352-2360. (Pubitemid 24322292)
33. Brandes AA, Franceschi E, Tosoni A, et al. Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer 2007; 110:2035-2041. (Pubitemid 350036864)
34. Brandes AA, Franceschi E, Tosoni A, et al. Efficacy of tailored treatment for high-and low-risk medulloblastoma in adults: a large prospective phase II trial. In: Abstracts of American Society of Clinical Oncology Annual Meeting; 4-8 June 2010; Chicago, IL. 2010; 28:2003.
35. Brandes AA, Franceschi E, Tosoni A, et al. Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol 2009; 71:165-179.
36. Spreafico F, Massimino M, Gandola L, et al. Survival of adults treated for medulloblastoma using paediatric protocols. Eur J Cancer 2005; 41:1304-1310. (Pubitemid 40813007)
37. Fernandez-Teijeiro A, Betensky RA, Sturla LM, et al. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 2004; 22:994-998. (Pubitemid 41095030)
38. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415:436-442. (Pubitemid 34100955)
39. Ellison DW, Onilude OE, Lindsey JC, et al. Beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005; 23:7951-7957. (Pubitemid 46657395)
40. Rutkowski S, von Bueren A, von Hoff K, et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 2007; 13:2651-2657. (Pubitemid 46788032)
41. Grotzer MA, Janss AJ, Phillips PC, Trojanowski JQ. Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. Klin Padiatr 2000; 212:196-199. (Pubitemid 30650554)
42. Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001; 85:705-712. (Pubitemid 32929469)
43. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004; 22:984-993. (Pubitemid 41095029)
44. Lamont JM, McManamy CS, Pearson AD, et al. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004; 10:5482-5493. (Pubitemid 39100486)
45. Pfister S, Hartmann C, Korshunov A. Histology and molecular pathology of pediatric brain tumors. J Child Neurol 2009; 24:1375-1386.
46. Herms J, Neidt I, Luscher B, et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 2000; 89:395-402.
47. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004; 63:441-449. (Pubitemid 38669665)
48. Traenka C, Remke M, Korshunov A, et al. Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Cancer Res 2010; 70:8003-8014.
49. Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011; 29:1400-1407.
50. Schwalbe EC, Lindsey JC, Straughton D, et al. Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res 2011; 17: 1883-1894.
51. ThompsonMC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006; 24:1924-1931. (Pubitemid 46638992)
52. Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29:1424-1430.
53. Tamayo P, Cho YJ, Tsherniak A, et al. Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol 2011; 29:1415-1423.
54. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29:1408-1414.
55. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008; 3:e3088.
56. Korshunov A, Remke M, Werft W, et al. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 2010; 28:3054-3060.
57. Remke M, Hielscher T, Northcott PA, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 2011; 29:2717-2723.
58. Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010; 468:1095-1099.
59. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24:4202-4208. (Pubitemid 46622300)
60. Monje M, Beachy PA, Fisher PG. Hedgehogs, flies, Wnts and MYCs: the time has come for many things in medulloblastoma. J Clin Oncol 2011; 29:1395-1398.
61. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173-1178.